In its response to the statement of objections, Aventis points out that it has initiated extensive compliance programmes, which resulted in the disclosure of other agreements. It was a mistake that the methylglucamine agreement was not identified and disclosed to the Commission(152).
Recital 259, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002